Dubai Investments' MoUs drive regional pharma, glass collaboration at Qatar Industrial Summit
The agreements, supported by MoIAT (Ministry of Industry and Advanced Technology), align with regional efforts to accelerate industrial growth, enhance economic collaboration, and drive sustainable development across key sectors.
As part of the expanding pharmaceutical collaboration within the region, GlobalPharma, a leading generics partner, signed an MoU with Morocco's Zenith Pharma.
The agreement focuses on technology transfer, licensing, and local manufacturing of critical medications, including injectable biologics, cholesterol treatments, and diabetes solutions.
With an investment exceeding $50 million, the partnership aims to bolster pharmaceutical security and enhance local production capabilities across member countries.
Emirates Float Glass (EFG) signed an MoU to supply high-quality float glass to a regional manufacturing company specializing in glass and silver mirror production.
Under the terms of the MoU, EFG will leverage its advanced production capabilities to ensure a steady and high-quality supply of glass, aligning with broader efforts to enhance regional supply chains and industrial self-sufficiency.
The agreements, signed at the Integrated Industrial Partnership for Sustainable Economic Development attended by industry ministers from the UAE, Egypt, Jordan, Bahrain, Morocco, Qatar, and Turkey, marked a significant milestone, further expanding cross-border cooperation and investment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
24-06-2025
- Khaleej Times
Dubai Investments strengthens its foothold in the region's glass manufacturing landscape
Pioneering industrial progress through precision, performance, and purpose-built glass solutions In a region defined by rapid transformation and development goals, the demand for high-performance, sustainable building materials keeps rising. Leading that change is Dubai Investments, a company whose legacy in industrial manufacturing continues to shape the future of the GCC's built environment. Recognising the long-term potential of glass as a high-value, design-forward, and performance-driven material, Dubai Investments had established Glass LLC as a dedicated holding company to consolidate its glass manufacturing entities. This strategic structure has enabled the group to align with the region's accelerating infrastructure growth and increasing emphasis on sustainability; positioning it at the forefront of industrial innovation. With deep-rooted expertise in the broader building materials sector, Dubai Investments has developed a diversified platform that supports the region's most ambitious infrastructure and real estate projects. However, it is in glass manufacturing - an area experiencing rapid innovation and growing global relevance - where the company is currently witnessing exceptional momentum. Established to streamline operations and drive synergies across Emirates Float Glass, Emirates Glass, and Saudi American Glass, Glass LLC serves as the group's response to rising demand for integrated, value-added glass solutions across regional megaprojects. Through its dedicated industrial subsidiary, Glass LLC, Dubai Investments is not only scaling production but also setting new benchmarks in design, sustainability, and regional impact. As glass evolves from a basic construction material to a smart, design-led and eco-conscious solution, the group is positioning itself at the cutting edge of this transformation. A clear vision: Glass as a strategic growth engine The performance of Dubai Investments' glass businesses in 2024 underscores the sector's growing importance, both in regional development and the global supply chain. Across its three key subsidiaries, Emirates Float Glass (EFG); Emirates Glass (EG); and Saudi American Glass (SAG), the group recorded a combined production output of 14.8 million square metres (sqm), reflecting consistent double-digit growth. This surge is driven by a combination of factors: rising demand from mega infrastructure projects in the UAE and Saudi Arabia, a growing shift toward sustainable and energy-efficient materials, and a bold commitment to manufacturing innovation. Emirates Float Glass: At full capacity and going global 2024 marked a pivotal year for Emirates Float Glass, which reached full production capacity and exported over 12.6 million sqm of float glass to markets across five continents. EFG stands as the only ICV-certified float glass manufacturer in the UAE, a critical advantage in government-backed development projects that prioritise local value creation. The company's inclusion in the Golden List by the Abu Dhabi Department of Economic Development is further testament to its national significance. Its diverse product range, including Clear, Tinted, Reflective, and Low-E glass, supports high-performance architectural designs and energy-efficient buildings. Emirates Glass: Expanding capabilities and design possibilities At Emirates Glass, 2024 brought both scale and sophistication. The company delivered 1.3 million+ sqm of processed glass, representing 8 per cent year-on-year growth, with output peaking at 28 per cent higher during key months. A major driver of this growth has been the company's investment in jumbo processing lines, which allow for precision cutting, tempering, and lamination on a larger scale. Emirates Glass also expanded its portfolio with fire-rated and bullet-resistant glass and launched a new digital printing unit; a game changer for architects seeking bespoke, large-format designs. Saudi American Glass: Design-led growth in the Kingdom Saudi American Glass (SAG), too, had a record year, delivering over 927,000 sqm in 2024; a 13 per cent increase from the previous year. SAG's design-led products, particularly under its Elite Vitrage brand, are seeing strong uptake across high-end residential, commercial, and hospitality projects. There's growing demand for artistic and digitally printed glass, and with Saudi Arabia's construction boom continuing through Vision 2030, the company expects this segment alone to grow by 57 per cent in 2025. Aligning with sustainability and regional visions At a time when the UAE is pushing ahead with its Net Zero 2050 Strategic Initiative and Saudi Arabia is realising its Vision 2030 goals, Dubai Investments' glass companies are playing an active role in supporting these missions. From solar control and Low-E technologies to green-certified manufacturing, the group's solutions are purpose-built for today's sustainable building mandates. Its export footprint, spanning 35+ countries, also reinforces the UAE's ambitions of becoming a global industrial hub. Building tomorrow with vision and purpose Dubai Investments, through its integrated glass manufacturing ecosystem, is not just keeping pace with this evolution, it is actively shaping it. By investing in technology, expanding capacity, and staying ahead of sustainability regulations, the group is setting new benchmarks for what locally manufactured glass can achieve. With Glass LLC, Dubai Investments is not only manufacturing at scale - it's reshaping the narrative around local industrial capability. From pioneering smart façades to enabling carbon-efficient cities, the group's glass business is now a pillar of both economic diversification and design excellence across the region. From curtain walls that reflect the region's architectural ambition to interiors that blend functionality with art, glass is fast becoming one of the most technically advanced and strategically important materials in the modern construction landscape. And with Dubai Investments at the helm, the region is better equipped than ever to build smarter, greener, and more resilient cities.
Arabian Business
18-06-2025
- Arabian Business
Pane and gain: Dubai Investments glass division shatters production record with 14.8 million sqm in 2024
Dubai Investments has reported record-breaking growth across its glass manufacturing portfolio, with production exceeding 14.8 million square meters in 2024. The surge reflects increased demand from regional mega projects and the company's continued investment in advanced, sustainable glass technologies. Glass LLC, a wholly owned subsidiary of Dubai Investments, oversees the group's glass operations and includes: Emirates Glass (EG) Emirates Float Glass (EFG) Saudi American Glass (SAG) Dubai glass manufacturing The three manufacturers serve the construction, architecture, transport, and energy sectors across the GCC and beyond. Abdulaziz Bin Yagub Al Serkal, CEO, Industrial Platform, Dubai Investments, said: 'The glass sector is a cornerstone of Dubai Investments' industrial platform—driving significant growth and reinforcing the Group's leadership in the GCC's high-performance materials market. 'As the region advances through mega projects and places greater emphasis on sustainability, Dubai Investments glass businesses are well-positioned to lead through innovation and product excellence. 'Continuous investments in cutting-edge technologies are sharpening the Group's competitive edge, enabling it to meet evolving industry needs while laying a strong foundation for long-term market leadership'. Emirates Float Glass (EFG), the UAE's only ICV-certified float glass manufacturer, produced over 12.6 million sqm of glass, reaching full production capacity in 2024 and exporting to five continents. EFG is listed on Abu Dhabi's Golden List for its contribution to national industrial development and is a key participant in the UAE's Projects of the 50 and Abu Dhabi Local Content Program. Emirates Glass (EG) reported an 8 per cent year-on-year production increase, contributing over 1.3 million sqm in 2024. Growth peaked at 28 per cent in December, thanks to investments in jumbo glass processing lines. Meanwhile, Saudi American Glass (SAG) achieved a 13 per cent annual increase, producing 927,000 sqm—its highest-ever output. A 48 per cent spike in digitally printed architectural glass demand has driven the success of Elite Vitrage, SAG's new artistic interior glass brand, with 57 per cent additional growth forecasted for 2025. Together, the companies under Glass LLC export to over 35 global markets, including the GCC, Africa, Europe, and Asia. Dubai Investments continues to invest in automation, capacity expansion, and next-gen technologies, ensuring it remains a leading force in the region's transition to sustainable infrastructure and advanced building materials.
Zawya
22-05-2025
- Zawya
Globalpharma inks 4 strategic MoUs during ‘Make it in the Emirates 2025'
'These partnerships are enhancing the country's position as a global hub for high-quality, future-ready healthcare solutions' - Dr. Thani Al Zeyoudi Abu Dhabi, UAE – Globalpharma, the UAE's leading pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments PJSC, has signed 4 strategic Memorandums of Understanding (MoUs) during the Make it in the Emirates Forum 2025. The agreements reinforce the UAE's position as a regional hub for pharmaceutical innovation, localization, and advanced healthcare manufacturing. The MoUs were signed individually with each partner, reflecting Globalpharma's tailored approach to strategic collaboration. The agreements were concluded with four international players — PharmaPrimes Laboratories (Jordan), Nerhadou International (Egypt), Aora Health (Spain), and BioSyent Pharma Inc. (Canada). His Excellency Dr. Thani Al Zeyoudi, UAE Minister of State for Foreign Trade and Chairman of the Emirates Drug Establishment witnessed the signing ceremonies with PharmaPrimes Laboratories, Nerhadou International, and Aora Health. These partnerships span critical areas such as technology transfer, product licensing, supply, and local manufacturing. Aligned with the UAE's industrial strategy, the collaborations aim to bolster domestic production, reduce reliance on imports, and accelerate access to next-generation healthcare solutions across the region. 'The strategic collaborations announced by Globalpharma during 'Make it in the Emirates' reflect the UAE's commitment to strengthening domestic pharmaceutical manufacturing and reducing reliance on imports. These partnerships embody the core goals of the 'Make it in the Emirates' initiative—empowering local industry, accelerating innovation, and enhancing the country's position as a global hub for high-quality, future-ready healthcare solutions,' stated His Excellency Dr. Thani Al Zeyoudi, UAE Minister of State for Foreign Trade and Chairman of the Emirates Drug Establishment. "Dubai Investments' long-term strategy is rooted in enabling sectors that drive national progress, and healthcare is central to that vision. These strategic partnerships by Globalpharma reflect the commitment to advancing the UAE's industrial capabilities, promoting knowledge transfer, and building a resilient pharmaceutical ecosystem that supports regional health security and innovation-driven growth," said Mohammed Saeed Al Raqbani, General Manager of Dubai Investments Industries and Masharie and Board Director at Globalpharma. Among the signings, PharmaPrimes Laboratories, a leading CRO based in Amman, Jordan, has signed a strategic partnership with Globalpharma to establish advanced local capabilities for batch release and analysis of biosimilar drugs in the United Arab Emirates. This partnership reflects PharmaPrimes' commitment to strengthening quality infrastructure and providing high-quality, cost-competitive biosimilar therapies across the GCC countries, enhancing the competitiveness of the pharmaceutical sector and improving healthcare quality in the region. In another major agreement, Nerhadou International, one of Egypt's foremost nutraceutical companies, joined forces with Globalpharma to introduce a portfolio of innovative nutraceutical and over the counter (OTC) products tailored to regional health needs. The collaboration is expected to reinforce the UAE's wellness landscape by promoting preventive care and healthier lifestyles. Further expanding its footprint in the wellness space, Globalpharma entered a collaboration with Aora Health, a Spanish company known for its science-driven approach to functional supplements. The partnership will see the co-development and local manufacturing of a premium range of preventive health supplements, enabling quicker market access to European-quality wellness products across the UAE and the MENA region. Rounding out the series of partnerships, Globalpharma signed a Licensing and Supply Agreement with BioSyent Pharma Inc, a specialty pharmaceutical company committed to improving the lives of patients with unique and effective products in Canada and select international markets. The agreement covers the introduction of FeraMAX®, a patented oral iron supplement known for its high bioavailability and reduced gastrointestinal side effects. Globalpharma will undertake secondary packaging and marketing of the product within the UAE. About Globalpharma Globalpharma is a wholly owned subsidiary of Dubai Investments PJSC. Established in 1998, Globalpharma is currently a market leader in key generic pharma segments with a strong regional footprint. Globalpharma started its operations in the UAE in 2003 and expanded its growth in 2008 with product line extensions and new product launches across 14 countries in the GCC and select African markets. Currently Globalpharma has two Manufacturing plants, A state of the art Beta-Lactam Penicillin Manufacturing plant providing the Amoxicillin & AmoxiClav brands in the larger MENA region. Additionally, catering to the Lifestyle disease segments, is a General Medicine Manufacturing Plant with a variety of Liquid & Oral Solid Dose capabilities. About PharmaPrimes Laboratories PharmaPrimes Laboratories is a CRO company offering comprehensive services in drug development and delivery systems, with a strong focus on innovation and delivering effective, high-quality therapeutic solutions in the Middle East and selected global markets. Its services include Research & Development, Pharmaceutical Quality Control, Biosimilar Testing and Analysis, and Bioanalysis and Bioequivalence Studies. PharmaPrimes is committed to the highest standards of quality and international regulations to ensure reliable and efficient service delivery. About Nerhadou International Established in 1996, Nerhadou International is a leading Egyptian pharmaceutical and nutraceutical manufacturer headquartered in 6th of October City, Giza. The company pioneer's innovative healthcare solutions, including oral dispersible film (ODF) technology, and is ranked among Egypt's top 50 pharmaceutical companies for six consecutive years. With a strong presence across the Middle East and Africa, Nerhadou is committed to delivering high-quality, affordable products that enhance health and well-being. About Aora Health Aora Health is a Spain-based nutraceutical company focused on science-backed, condition-specific supplements. With a strong emphasis on research and innovation, Aora delivers high-quality products across key health segments, including digestive, cognitive, and women's health. About BioSyent Pharma Inc BioSyent Pharma Inc is a Canadian specialty pharmaceutical company dedicated to enhancing patient outcomes through innovative, in-licensed healthcare products. With a diverse portfolio spanning therapeutic areas such as iron deficiency, pain management, women's health, and oncology support, BioSyent delivers clinically proven solutions to patients and healthcare professionals across Canada and select international markets. The company is publicly traded on the TSX Venture Exchange under the symbol 'RX'.
